Skip to main content
. Author manuscript; available in PMC: 2017 Jun 14.
Published in final edited form as: JAMA. 2016 Jun 14;315(22):2415–2423. doi: 10.1001/jama.2016.7789

Table 3.

Mortality according to underlying cause of death.

Anticonvulsant or Cyclic Antidepressant (8,066 person-years follow-up) Long-acting Opioid (11,070 person-years follow-up) Adjusted Hazard Ratioa (95% CI) Adjusted Risk Differencea,b (95% CI) p
Deaths Incidence/10,000 Person-Years Deaths Incidence/10,000 Person-Years
All deaths 87 107.9 185 167.1 1.64 (1.26–2.12) 68.5 (28.2–120.7) <.001
 Out-of-hospital deaths 60 74.4 154 139.1 1.90 (1.40–2.58) 67.1 (30.1–117.3) <.001
 Unintentional overdose deathsc 7 8.7 34 30.7 3.37 (1.47–7.70) 20.6 (4.1–58.1) 0.004
 Other causes of death 53 65.7 120 108.4 1.72 (1.24–2.39) 47.4 (15.7–91.4) 0.001
  Cardiovascular 36 44.6 79 71.4 1.65 (1.10–2.46) 28.9 (4.6–65.3) 0.015
  Respiratory 3 3.7 10 9.0 3.00 (0.81–11.09) 7.4 (−0.7–37.5) 0.100
  Other Injury 11 13.6 19 17.2 1.15 (0.54–2.47) 2.1 (−6.3–20.0) 0.716
  Other 3 3.7 12 10.8 3.72 (1.04–13.30) 10.1 (0.2–45.7) 0.043
Hospital Deaths 27 33.5 31 28.0 1.00 (0.59–1.69) 0.0 (−13.6–23.1) 0.996
a

Adjusted for baseline propensity score decile and age and calendar year during followup.

b

Risk differences for the specific causes of death do not sum because the regression model parameters are estimated separately for each cause.

c

The cohort excluded patients with a diagnosis of or procedure for treatment of substance abuse other than nicotine or alcohol as well as those prescribed buprenorphine. Because such patients would plausibly have increased risk for overdose, overdose mortality in the study cohort is likely to be lower than that in a more general patient population.